Editas Medicine, Inc. is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. Its platform consists of four components: nuclease engineering, delivery, control and specificity, and directed editing. Its programs include Eye Diseases, Engineered T Cell Therapies for Immuno-Oncology and additional research programs. It is developing a genome editing therapeutic for Leber Congenital Amaurosis type 10 (LCA10).
Industry, Sector and Symbol:
- Market Cap: $704.61 million
- Outstanding Shares: 40,729,000
- 50 Day Moving Avg: $19.57
- 200 Day Moving Avg: $19.03
- 52 Week Range: $12.43 - $38.25
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -6.53
- P/E Growth: 0.00
- Annual Revenue: $5.93 million
- Price / Sales: 118.82
- Book Value: $5.07 per share
- Price / Book: 3.41
- EBIDTA: ($108,330,000.00)
- Net Margins: -1,184.46%
- Return on Equity: -59.22%
- Return on Assets: -31.66%
- Debt-to-Equity Ratio: 0.19%
- Current Ratio: 14.80%
- Quick Ratio: 14.80%
- Average Volume: 894,527 shs.
- Short Ratio: 3.78
Frequently Asked Questions for Editas Medicine (NASDAQ:EDIT)
What is Editas Medicine's stock symbol?
Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."
How were Editas Medicine's earnings last quarter?
Editas Medicine Inc (NASDAQ:EDIT) posted its quarterly earnings data on Monday, May, 15th. The company reported ($0.85) EPS for the quarter, missing the Zacks' consensus estimate of ($0.62) by $0.23. The business earned $0.68 million during the quarter, compared to analysts' expectations of $1 million. Editas Medicine had a negative net margin of 1,184.46% and a negative return on equity of 59.22%. The firm's quarterly revenue was down 16.0% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.80) earnings per share. View Editas Medicine's Earnings History.
Where is Editas Medicine's stock going? Where will Editas Medicine's stock price be in 2017?
4 brokers have issued 1 year price objectives for Editas Medicine's stock. Their forecasts range from $32.00 to $35.00. On average, they anticipate Editas Medicine's stock price to reach $33.50 in the next twelve months. View Analyst Ratings for Editas Medicine.
What are analysts saying about Editas Medicine stock?
Here are some recent quotes from research analysts about Editas Medicine stock:
- 1. According to Zacks Investment Research, "Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts. " (3/28/2017)
- 2. Chardan Capital analysts commented, "We initiate coverage of Editas Medicine (EDIT) with a Buy rating (PT $65), on our view of the company's IP breadth and strength providing significant upside potential for shares, via both internal and partnered program opportunities. Editas is a preclinical biotech company aiming to treat various genetic conditions through the CRISPR gene editing system, in which a CRISPR guide RNA (gRNA) delivers a nuclease (a sort of "DNA scissors") to specifically modify a particular DNA sequence to treat diseases. Editas' lead asset, targeting Leber's congenital amaurosis type 10 (LCA10), could be one of the first CRISPR therapies to enter the clinic. An IND filing is expected by year-end 2017." (3/27/2017)
- 3. Cowen and Company analysts commented, "Today Editas partnered its ophthalmology CRISPR programs with Allergan for $90MM." (3/15/2017)
- 4. Jefferies Group LLC analysts commented, "We gained incremental color on IP and pipeline progress from our meeting. Mgmt continues to be confident about their broad IP portfolio, which allows them to be prepared for any possible outcome from ongoing interference proceedings. The LCA10 IND filing remains on track by YE17 and likely would require a RAC meeting. Mgmt laid out key elements for the IND filing package and expect to present NHP data at medical meetings in 2017." (2/15/2017)
Who are some of Editas Medicine's key competitors?
Some companies that are related to Editas Medicine include Myriad Genetics (MYGN), CONMED (CNMD), Aerie Pharmaceuticals (AERI), Foundation Medicine (FMI), Phibro Animal Health Corp (PAHC), Corcept Therapeutics Incorporated (CORT), Glaukos Corp (GKOS), Innoviva (INVA), Repligen (RGEN), Loxo Oncology (LOXO), Blueprint Medicines Corp (BPMC), Tivity Health (TVTY), Global Blood Therapeutics (GBT), Emergent Biosolutions (EBS), Amicus Therapeutics (FOLD), Dermira (DERM), Eagle Pharmaceuticals (EGRX) and Coherus Biosciences (CHRS).
When did Editas Medicine IPO?
(EDIT) raised $100 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.
Who owns Editas Medicine stock?
Editas Medicine's stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (16.47%), Polaris Venture Management Co. VI L.L.C. (10.59%), Flagship Pioneering Inc. (9.42%), Vanguard Group Inc. (5.40%), Clough Capital Partners L P (1.09%) and Morgan Stanley (0.86%). Company insiders that own Editas Medicine stock include Alexandra Glucksmann, Andrew A F Hack, James E Flynn, Kevin Bitterman, Kevin P Starr and Polaris Venture Management Co. View Institutional Ownership Trends for Editas Medicine.
Who sold Editas Medicine stock? Who is selling Editas Medicine stock?
Editas Medicine's stock was sold by a variety of institutional investors in the last quarter, including Flagship Pioneering Inc., Credit Suisse AG, ProShare Advisors LLC and TIAA CREF Investment Management LLC. Company insiders that have sold Editas Medicine stock in the last year include Alexandra Glucksmann, Andrew A F Hack, Kevin Bitterman, Kevin P Starr and Polaris Venture Management Co. View Insider Buying and Selling for Editas Medicine.
Who bought Editas Medicine stock? Who is buying Editas Medicine stock?
Editas Medicine's stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., FMR LLC, Clough Capital Partners L P, LMR Partners LLP, York Capital Management Global Advisors LLC, Morgan Stanley, Driehaus Capital Management LLC and UBS Group AG. View Insider Buying and Selling for Editas Medicine.
How do I buy Editas Medicine stock?
Shares of Editas Medicine can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Editas Medicine stock cost?
One share of Editas Medicine stock can currently be purchased for approximately $17.30.
Earnings History for Editas Medicine (NASDAQ:EDIT)Earnings History by Quarter for Editas Medicine (NASDAQ:EDIT)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/15/2017||Q1 2017||($0.62)||($0.85)||$1.00 million||$0.68 million||View||N/A|
|3/7/2017||Q4 2016||($0.62)||($1.10)||$1.11 million||$0.90 million||View||Listen|
|11/7/2016||Q3||($0.64)||($0.59)||$1.00 million||$1.00 million||View||Listen|
|8/9/2016||Q2||($0.54)||($0.54)||$3.52 million||$3.39 million||View||Listen|
|5/16/2016||Q116||($0.23)||($0.80)||$1.08 million||$0.80 million||View||Listen|
Earnings Estimates for Editas Medicine (NASDAQ:EDIT)
2017 EPS Consensus Estimate: ($2.86)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Editas Medicine (NASDAQ:EDIT)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Editas Medicine (NASDAQ:EDIT)
Institutional Ownership Percentage: 60.89%Insider Trades by Quarter for Editas Medicine (NASDAQ:EDIT)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|3/15/2017||Alexandra Glucksmann||COO||Sell||1,000||$26.41||$26,410.00|| |
|2/15/2017||Alexandra Glucksmann||COO||Sell||6,000||$20.58||$123,480.00|| |
|2/15/2017||Andrew A F Hack||CFO||Sell||3,000||$19.20||$57,600.00|| |
|1/11/2017||Andrew A F Hack||CFO||Sell||15,000||$19.20||$288,000.00|| |
|12/7/2016||Polaris Venture Management Co.||Major Shareholder||Sell||75,000||$15.82||$1,186,500.00|| |
|12/6/2016||Kevin Bitterman||Director||Sell||130,000||$15.79||$2,052,700.00|| |
|11/23/2016||Kevin Bitterman||Director||Sell||21,480||$15.71||$337,450.80|| |
|11/22/2016||Polaris Venture Management Co.||Major Shareholder||Sell||12,819||$15.77||$202,155.63|| |
|11/15/2016||Kevin Bitterman||Director||Sell||88,900||$16.96||$1,507,744.00|| |
|9/8/2016||Polaris Venture Management Co.||Major Shareholder||Sell||500,000||$16.80||$8,400,000.00|| |
|9/6/2016||Kevin P. Starr||Major Shareholder||Sell||5,890||$15.90||$93,651.00|| |
|8/23/2016||Alexandra Glucksmann||COO||Sell||1,000||$20.00||$20,000.00|| |
|2/8/2016||James E Flynn||Insider||Buy||100,000||$16.00||$1,600,000.00|| |
Headline Trends for Editas Medicine (NASDAQ:EDIT)
Latest Headlines for Editas Medicine (NASDAQ:EDIT)
|Editas Medicine Inc (EDIT) Receives Consensus Recommendation of "Buy" from Brokerages|
www.americanbankingnews.com - May 19 at 2:02 PM
|Editas Medicine Announces First Quarter 2017 Results and Update ... - Nasdaq|
www.nasdaq.com - May 16 at 4:51 PM
|Editas Medicine Inc. (EDIT) Is Falling After Q1 Loss Widens|
www.rttnews.com - May 16 at 11:57 AM
|Editas reports 1Q loss|
finance.yahoo.com - May 16 at 11:57 AM
|Edited Transcript of EDIT earnings conference call or presentation 15-May-17 9:00pm GMT|
finance.yahoo.com - May 16 at 11:57 AM
|Editas Medicine Inc (EDIT) Posts Earnings Results, Misses Estimates By $0.14 EPS|
www.americanbankingnews.com - May 15 at 9:20 PM
|BRIEF-Editas Medicine Q1 loss per share $0.85|
www.reuters.com - May 15 at 4:40 PM
|Investor Network: Editas Medicine, Inc. to Host Earnings Call|
finance.yahoo.com - May 15 at 4:40 PM
|Editas Medicine Announces First Quarter 2017 Results and Update|
finance.yahoo.com - May 15 at 4:40 PM
|Why Editas Medicine (EDIT) Might Surprise This Earnings Season - Nasdaq|
www.nasdaq.com - May 14 at 9:18 AM
|Editas Medicine Demonstrates First Achievement of In Vivo Editing in Non-human Primate Retinas - GlobeNewswire (press release)|
www.globenewswire.com - May 14 at 9:18 AM
|Editas Medicine Demonstrates First Achievement of In Vivo Editing in Non-human Primate Retinas|
finance.yahoo.com - May 13 at 4:48 PM
|How Alphabet's venture arm is fueling the Mass. life science cluster|
www.bizjournals.com - May 12 at 5:21 PM
|Why Editas Medicine (EDIT) Might Surprise This Earnings Season|
finance.yahoo.com - May 12 at 5:21 PM
|Editas Medicine Announces Pre-Clinical Data for Program to Treat Sickle Cell Disease and Beta-Thalassemia - Nasdaq|
www.nasdaq.com - May 11 at 10:32 PM
|Editas Medicine Announces Pre-Clinical Data for Program to Treat Sickle Cell Disease and Beta-Thalassemia|
finance.yahoo.com - May 11 at 5:31 PM
|Editas Medicine to Present at Investor Conferences in May - GlobeNewswire (press release)|
globenewswire.com - May 9 at 7:32 AM
|Editas Medicine to Host Conference Call Discussing First Quarter 2017 Corporate Update and Results|
finance.yahoo.com - May 8 at 4:46 PM
|Editas Medicine to Present at Investor Conferences in May|
finance.yahoo.com - May 8 at 4:46 PM
|Can Ligand (LGND) Spring a Surprise this Earnings Season?|
www.nasdaq.com - May 4 at 11:43 AM
|CEOs of top gene-editing firms got huge compensation hikes last year|
finance.yahoo.com - April 27 at 5:26 PM
|Today's Bell Ringer, April 25, 2017|
finance.yahoo.com - April 25 at 11:39 AM
|Editas Medicine (EDIT) to Present New Data Showing Advancements for Translating CRISPR Technologies into Medicines at ASGCT|
www.streetinsider.com - April 24 at 4:45 PM
|Editas Medicine, Inc. (Nasdaq: EDIT) to Ring The Nasdaq Stock Market Opening Bell|
finance.yahoo.com - April 24 at 4:45 PM
|Editas Medicine Inc (EDIT) Given Average Rating of "Buy" by Analysts|
www.americanbankingnews.com - April 24 at 1:54 PM
|$1.08 Million in Sales Expected for Editas Medicine Inc (EDIT) This Quarter|
www.americanbankingnews.com - April 22 at 8:11 AM
|Zacks: Analysts Anticipate Editas Medicine Inc (EDIT) to Post -$0.63 EPS|
www.americanbankingnews.com - April 20 at 6:05 PM
|Editas foes add legal firepower as gene-editing case goes to appeal|
finance.yahoo.com - April 13 at 4:50 PM
|Editas Medicine Inc (EDIT) Receives Average Rating of "Buy" from Brokerages|
www.americanbankingnews.com - April 4 at 9:17 AM
|Zacks Investment Research Upgrades Editas Medicine Inc (EDIT) to Hold|
www.americanbankingnews.com - April 3 at 8:50 AM
|EDITAS MEDICINE, INC. Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an Off-Bal|
biz.yahoo.com - March 31 at 4:59 PM
|New Cambridge biotech Tango aims to make cancer its own worst enemy|
www.bizjournals.com - March 30 at 5:20 PM
|Zacks Investment Research Upgrades Editas Medicine Inc (EDIT) to "Hold"|
www.americanbankingnews.com - March 28 at 7:28 PM
|Coverage initiated on Editas Medicine by Chardan Capital Markets|
finance.yahoo.com - March 28 at 12:03 PM
|Editas Medicine Inc (EDIT) Coverage Initiated by Analysts at Chardan Capital|
www.americanbankingnews.com - March 27 at 6:27 PM
|Vetr Inc. Upgrades Editas Medicine Inc (EDIT) to "Strong-Buy"|
www.americanbankingnews.com - March 26 at 12:04 AM
|Editas Medicine Inc (EDIT) Upgraded to Strong-Buy at Vetr Inc.|
www.americanbankingnews.com - March 24 at 7:20 AM
|Editas Get A Vetr Upgrade To Strong Buy|
finance.yahoo.com - March 21 at 8:21 AM
|EDITAS MEDICINE, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Stateme|
biz.yahoo.com - March 17 at 5:11 PM
|BRIEF-Editas announces pricing of $90 million offering of common stock|
www.reuters.com - March 16 at 11:17 PM
|Editas Medicine, Inc. Announces Pricing of $90 Million Offering of Common Stock|
finance.yahoo.com - March 16 at 11:17 PM
|Pig organs in humans? George Church-founded biotech banks $38M to try|
www.bizjournals.com - March 16 at 3:21 AM
|Allergan (AGN) and Editas Tie Up to Treat Eye Diseases|
www.zacks.com - March 15 at 5:17 PM
|BRIEF-Editas medicine announces proposed offering of common stock|
www.reuters.com - March 15 at 5:17 PM
|EDITAS MEDICINE, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement|
us.rd.yahoo.com - March 15 at 5:17 PM
|Editas Medicine, Inc., Announces Proposed Offering of Common Stock|
us.rd.yahoo.com - March 15 at 5:17 PM
|FDA Panel Snubs ENDP, Watch Out For TCON, MRK's Keytruda Scores Another Win|
www.nasdaq.com - March 15 at 2:20 AM
|UPDATE 1-Allergan signs deal with Editas for gene-editing-based eye treatments|
www.businessinsider.com - March 15 at 2:20 AM
|Editas Medicine Inc. (EDIT) Is Up Sharply After Allergan Alliance - Nasdaq|
www.nasdaq.com - March 14 at 4:17 PM
|Allergan plc and Editas Medicine Inc Enter into Strategic R&D Alliance to Discover and Develop CRISPR Genome Editing Medicines for Eye Diseases Call scheduled for 4:30 pm ET today|
biz.yahoo.com - March 14 at 4:17 PM
Editas Medicine (EDIT) Chart for Tuesday, May, 23, 2017